{"id":"furestem-ad-inj","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infection risk"},{"rate":null,"effect":"Immune reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of cultured mesenchymal stem cells derived from human adipose tissue that are administered via injection to affected skin areas. These cells are believed to work through immunomodulatory mechanisms, reducing inflammatory cytokine production and promoting anti-inflammatory responses, while also potentially enhancing tissue regeneration and barrier function in atopic dermatitis lesions.","oneSentence":"FURESTEM-AD is an allogeneic adipose tissue-derived mesenchymal stem cell product that modulates immune responses and promotes tissue repair in atopic dermatitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:05.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT04725136","phase":"PHASE1, PHASE2","title":"Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2021-01-27","conditions":"Atopic Dermatitis","enrollment":96},{"nctId":"NCT05004324","phase":"PHASE3","title":"Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD)","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2021-06-29","conditions":"Dermatitis, Atopic","enrollment":308},{"nctId":"NCT03962387","phase":"","title":"Evalution the Safety and Efficacy in Atopic Dermatitis Patients","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2019-04-05","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT04730024","phase":"","title":"Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj","status":"NOT_YET_RECRUITING","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2022-03-27","conditions":"Atopic Dermatitis","enrollment":102},{"nctId":"NCT03269773","phase":"PHASE3","title":"Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)","status":"COMPLETED","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2018-04-25","conditions":"Atopic Dermatitis","enrollment":197},{"nctId":"NCT04087863","phase":"","title":"Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2019-08-29","conditions":"Atopic Dermatitis","enrollment":99},{"nctId":"NCT03458624","phase":"","title":"Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.","status":"UNKNOWN","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2016-07-01","conditions":"Atopic Dermatitis","enrollment":14},{"nctId":"NCT01927705","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Kang Stem Biotech Co., Ltd.","startDate":"2013-09","conditions":"Atopic Dermatitis","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":799,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FURESTEM-AD Inj.","genericName":"FURESTEM-AD Inj.","companyName":"Kang Stem Biotech Co., Ltd.","companyId":"kang-stem-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"FURESTEM-AD is an allogeneic adipose tissue-derived mesenchymal stem cell product that modulates immune responses and promotes tissue repair in atopic dermatitis. Used for Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}